The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Instead of prescribing the drugs for "off-label use," pediatricians can now feel more confident when treating children with Hepatitis C. Schering-Plough's Rebetol and PEG-Intron have been officially approved by the FDA for treating Hepatitis C in kids aged 3 to 17.
Continue reading »A potential alternative to liver transplant surgery, stem cells from umbilical cord blood may be the solution that those living with chronic hepatitis have been looking for.
Continue reading »At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia.
Continue reading »An ongoing Phase IIa study on Schering-Plough’s next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH... View Article
Continue reading »Although it is early in the process and only involves a few subjects, interim trial results for ChronVac-C show extremely high percentages of Hepatitis C viral load reduction.
Continue reading »The relatively new field of proteomics may be able to predict who will respond to Hepatitis C therapy - before treatment even begins.
Continue reading »Three companies unite to begin an innovative Hepatitis C trial, where two oral antiviral drugs will be combined in the absence of interferon.
Continue reading »Viral clearance doubled in a Hepatitis C Phase II trial during standard therapy when coupled with GlobeImmune's GI-5005. Because Hepatitis C must be eradicated not just from the blood, but also the liver, GI-5005's ability to speed the clearance rate of infected cells from the liver shows great therapeutic promise.
Continue reading »Here's some news to be announced at next week's meeting of the American Association for the Study of Liver Diseases. Vertex Pharmaceuticals will release mid-stage study results indicating the effectiveness of its experimental drug, telaprevir. This recent study, known as Prove 3, focused on 453 patients who had failed previous treatment with pegylated-interferon and ribavirin. The exciting news is that 52 percent of them saw the virus fall to undetectable levels for a 12-week period following treatment. In this article you'll learn how telaprevir might shorten treatment time by half, whether reducing dosage frequency could affect its safety, and how sustained viral response rate is determined.
Continue reading »A specially designed breath test has been found to be a safe and accurate alternative to liver biopsy for determining the degree of inflammation and fibrosis in patients with chronic Hepatitis C infection and normal ALT, according to researchers from Jerusalem.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
